A three part, staggered cohort, open-label and double blind, randomized, placebo controlled study to investigate the efficacy, safety, tolerability and pharmacokinetics of eltrombopag, a thrombopoietin receptor agonist, in previously treated pediatric pat
Read time: 1 mins
Last updated:6th Jul 2009
To assess the efficacy of eltrombopag, relative to placebo, in achieving a platelet count ?50Gi/L at any time during a 6 week treatment period when administered to previously treated pediatric subjects with chronic ITP.
|Study start date||2009-07-06|